| scholarly article | Q13442814 |
| P2093 | author name string | Manish Kumar | |
| John Laterra | |||
| Roger Abounader | |||
| Elizabeth Johnson | |||
| David Schiff | |||
| Yongde Bao | |||
| Fadila Guessous | |||
| Isa Hussaini | |||
| Yunqing Li | |||
| Bachchu Lal | |||
| Lauren Fuller | |||
| Sherwin Kwon | |||
| Opeyemi Ibidapo | |||
| P2860 | cites work | A simplified system for generating recombinant adenoviruses | Q24682328 |
| Surfing the p53 network | Q28032484 | ||
| PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms | Q28181035 | ||
| Regulation of PTEN transcription by p53 | Q28646911 | ||
| Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. | Q32134611 | ||
| Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. | Q33931140 | ||
| The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth | Q34402080 | ||
| Pten signaling in gliomas | Q34707865 | ||
| The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network | Q34825957 | ||
| Transcriptional activities of mutant p53: when mutations are more than a loss | Q35902152 | ||
| p53 mutation heterogeneity in cancer | Q36113160 | ||
| Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways | Q36256326 | ||
| Tumours and tremors: how PTEN regulation underlies both | Q36404118 | ||
| Mutant p53 proteins: between loss and gain of function | Q36661775 | ||
| Transcription regulation by mutant p53. | Q36777349 | ||
| Tumor-derived p53 mutants induce NF-kappaB2 gene expression | Q39614332 | ||
| Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. | Q40200606 | ||
| The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy | Q40360944 | ||
| PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy | Q40765673 | ||
| Radiation-induced mutations at the autosomal thymidine kinase locus are not elevated in p53-null cells. | Q40943652 | ||
| The expression of both domains of the 69/71 kDa 2',5' oligoadenylate synthetase generates a catalytically active enzyme and mediates an anti-viral response | Q40956174 | ||
| The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells | Q40993616 | ||
| Induction of senescence in human malignant glioma cells by p16INK4A. | Q41098516 | ||
| Gain of function mutations in p53. | Q41557652 | ||
| Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. | Q42445479 | ||
| Genetic pathways to glioblastoma: a population-based study | Q44673208 | ||
| p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition | Q44762886 | ||
| PTEN regulates Mdm2 expression through the P1 promoter | Q44848220 | ||
| PTEN/MMAC1 mutations correlate inversely with an altered p53 tumor suppressor gene in gynecologic tumors | Q46682481 | ||
| Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines | Q48154511 | ||
| Functional evaluation of p53 and PTEN gene mutations in gliomas. | Q55475014 | ||
| PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner | Q57591077 | ||
| Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas | Q57591220 | ||
| Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression | Q73004517 | ||
| PTEN and p53: who will get the upper hand? | Q73086898 | ||
| p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 | Q79961068 | ||
| Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells | Q79961179 | ||
| Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome | Q81166001 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1723-1731 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations | |
| P478 | volume | 68 |
| Q30417988 | A Novel PTEN/Mutant p53/c-Myc/Bcl-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy |
| Q36941509 | ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation |
| Q30432036 | An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q36965370 | Applications of emerging molecular technologies in glioblastoma multiforme |
| Q39027066 | Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status |
| Q34965421 | Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma |
| Q46710025 | Coalterations of p53 and PTEN tumor suppressor genes in non–small cell lung carcinoma patients |
| Q30422676 | Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy |
| Q38112074 | Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme |
| Q34103978 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary |
| Q39557390 | Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas |
| Q34277174 | Evolutionary Pathways in BRCA1-Associated Breast Tumors |
| Q39307665 | HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. |
| Q30434675 | Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion |
| Q30437740 | Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy |
| Q30434616 | MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes |
| Q30405446 | Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma |
| Q26767396 | Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression Pathways |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q92940029 | Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers |
| Q93111131 | Overexpression of PTEN may increase the effect of pemetrexed on A549 cells via inhibition of the PI3K/AKT/mTOR pathway and carbohydrate metabolism |
| Q38238609 | PI3K/Akt-mediated regulation of p53 in cancer |
| Q92316075 | PTEN Tumor-Suppressor: The Dam of Stemness in Cancer |
| Q34514602 | PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation |
| Q34133079 | PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. |
| Q39844741 | PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma |
| Q37698905 | PTEN-mediated ERK1/2 inhibition and paradoxical cellular proliferation following Pnck overexpression |
| Q38406254 | PTEN: a yin-yang master regulator protein in health and disease |
| Q42921293 | PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma |
| Q28586781 | Personalized characterization of diseases using sample-specific networks |
| Q37158722 | Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia |
| Q38899532 | Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process |
| Q52584348 | Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer |
| Q39274129 | R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway |
| Q91810386 | RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas |
| Q36880907 | Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs |
| Q33574529 | Slit2 inhibits glioma cell invasion in the brain by suppression of Cdc42 activity. |
| Q38180665 | TP53 mutants in the tower of babel of cancer progression |
| Q36995054 | Targeting prostate cancer based on signal transduction and cell cycle pathways. |
| Q39740608 | Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma |
| Q24306770 | The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress |
| Q57162865 | The p53 Pathway in Glioblastoma |
| Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q38605143 | Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q57801751 | miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis |
| Q30428366 | microRNA-34a is tumor suppressive in brain tumors and glioma stem cells |
Search more.